Navigation Links
BioLife Solutions Modifies Existing Credit Facility
Date:7/5/2017

BOTHELL, Wash., July 5, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that it has reached an agreement with WAVI Holding AG, ("WAVI") its debt holder and largest shareholder, to modify its existing credit facility effective June 30, 2017.

Pursuant to the modification, WAVI agreed to exchange its existing $4.25 million credit facility, including principal and accrued interest outstanding as of June 1, 2017, for 4,250 shares of the Company's Series A Preferred Stock, which has a fixed, aggregate stated value of $4.25 million. The preferred shares being issued to WAVI are not convertible into any other form of equity and can only be redeemed at the stated value of $4.25 million at times and in amounts solely determined by the Company. The preferred shares also carry an annual cash dividend of 10% of the outstanding stated value, calculated and payable in arrears on a quarterly basis. No additional consideration was provided to WAVI for entering into this agreement.

"This modification will ensure that we continue to meet NASDAQ's minimum shareholder equity requirement of $2.5 million without any dilution to our common shareholders," said Roderick de Greef, BioLife's CFO. "The Company intends to redeem the preferred stock at the stated value of $4.25 million over the next five years, utilizing cash flow generated by operations. We have no plans to redeem or convert the Series A Preferred Stock using common shares."

About BioLife Solutions BioLife Solutions develops, manufactures and markets biopreservation media products and smart shipping containers connected to a cloud hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements, concerning the company's anticipated business and operations, and cash flows thereof, the intentions to redeem Series A Preferred Shares, and the use of common shares to redeem or convert the Series A Preferred Shares. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor RelationsRoderick de GreefChief Financial Officer(425) 686-6002 rdegreef@biolifesolutions.com


'/>"/>
SOURCE BioLife Solutions, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
2. BioLife Solutions Announces the Addition of Robert Preti, Ph.D. to its Scientific Advisory Board
3. BioLife Solutions and SAVSU Technologies Announce Exclusive Distribution Agreement
4. BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
5. BioLife Solutions Appoints Raymond W. Cohen as Chairman and Joe Schick to Board of Directors
6. BioLife Solutions Announces Manufacturing Agreement With Somahlution LLC
7. BioLife Solutions To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York City And The Aegis Healthcare & Technology Conference In Las Vegas
8. BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board
9. BioLife Solutions Biopreservation Media Products Used at NeoStem Subsidiary Progenitor Cell Therapy
10. BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014
11. BioLife Solutions Announces Third Quarter 2014 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):